Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
NCT ID: NCT00105144
Last Updated: 2014-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
611 participants
INTERVENTIONAL
2004-09-30
2006-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia
NCT00189709
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
NCT01982071
Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
NCT00106288
A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk Surgical Subjects
NCT01122368
Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)
NCT00083343
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
lower dose
Micafungin
IV
2
higher dose
Micafungin
IV
3
Caspofungin
IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Micafungin
IV
Caspofungin
IV
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients who have received more than two days of prior systemic antifungal therapy for the current infection.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Central Contact
Role: STUDY_DIRECTOR
Astellas Pharma US, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Little Rock, Arkansas, United States
Los Angeles, California, United States
Los Angeles, California, United States
San Francisco, California, United States
Denver, Colorado, United States
Denver, Colorado, United States
Washington D.C., District of Columbia, United States
Bay Pines, Florida, United States
Miami, Florida, United States
Atlanta, Georgia, United States
Augusta, Georgia, United States
Augusta, Georgia, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Maywood, Illinois, United States
Beech Grove, Indiana, United States
Evansville, Indiana, United States
Des Moines, Iowa, United States
Iowa City, Iowa, United States
Kansas City, Kansas, United States
Wichita, Kansas, United States
Lexington, Kentucky, United States
New Orleans, Louisiana, United States
Baltimore, Maryland, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Detroit, Michigan, United States
Detroit, Michigan, United States
Minneapolis, Minnesota, United States
Jackson, Mississippi, United States
St Louis, Missouri, United States
Neptune City, New Jersey, United States
Albany, New York, United States
Manhasset, New York, United States
New Hyde Park, New York, United States
New York, New York, United States
New York, New York, United States
Rochester, New York, United States
Stony Brook, New York, United States
The Bronx, New York, United States
Valhalla, New York, United States
Durham, North Carolina, United States
Winston-Salem, North Carolina, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Allentown, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
West Reading, Pennsylvania, United States
Providence, Rhode Island, United States
Jackson, Tennessee, United States
Memphis, Tennessee, United States
Dallas, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
Charlottesville, Virginia, United States
Fairfax, Virginia, United States
Seattle, Washington, United States
Vienna, , Austria
Aalst, , Belgium
Brussels, , Belgium
Brussels, , Belgium
Brussels, , Belgium
Brussels, , Belgium
Ghent, , Belgium
Liège, , Belgium
Belo Horizonte, Mg-cep, Brazil
Belo Horizonte, Mg-cep, Brazil
Belo Horizonte, Minas Gerais, Brazil
Cunitiba, Pr-cep, Brazil
Rio de Janeiro, Rio de Janeiro, Brazil
Porto Alegre, Rio Grande do Sul, Brazil
Santos, São Paulo, Brazil
São José do Rio Preto, São Paulo, Brazil
São Paulo, São Paulo, Brazil
Belo Horizonte, , Brazil
Belo Horizonte, , Brazil
Belo Horizonte, , Brazil
Salvador, , Brazil
Salvador, , Brazil
São Paulo, , Brazil
São Paulo, , Brazil
São Paulo, , Brazil
Edmonton, Alberta, Canada
Kelowna, British Columbia, Canada
Winnipeg, Manitoba, Canada
St. John's, Newfoundland and Labrador, Canada
Halifax, Nova Scotia, Canada
Hamilton, Ontario, Canada
Kingston, Ontario, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Chicoutimi, Quebec, Canada
Greenfield Park, Quebec, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Québec, Quebec, Canada
Regina, Saskatchewan, Canada
Saskatoon, Saskatchewan, Canada
Zagreb, , Croatia
Prague, , Czechia
Bobigny, , France
Metz, , France
Paris, , France
Paris, , France
Paris, , France
Paris, , France
Strasbourg, , France
Villejuif, , France
Villejuif, , France
Berlin, , Germany
Bielefeld, , Germany
Cologne, , Germany
Frankfurt, , Germany
Hanover, , Germany
Ulm, , Germany
Würzburg, , Germany
Bangalore, , India
Bangalore, , India
Bangalore, , India
Banglore, , India
Chandigarh, , India
Chennai, , India
Chennai, , India
Cochin Kerala, , India
Hyderabad, , India
Hyderabad, , India
Hyderabad, , India
Hyderabad, , India
Kochi, , India
Kolkotta, , India
Lucknow, , India
Ludhiana, , India
Mangalore, , India
Manipal, , India
Mumbai, , India
Mumbai, , India
Uttar Pradesh, , India
Groningen, , Netherlands
Gdansk, , Poland
Lodz, , Poland
Warsaw, , Poland
Barakaldo, , Spain
Barcelona, , Spain
Barcelona, , Spain
Barcelona, , Spain
Barcelona, , Spain
Madrid, , Spain
Madrid, , Spain
Madrid, , Spain
Madrid, , Spain
Salamanca, , Spain
Santander, , Spain
Seville, , Spain
Valencia, , Spain
Sankt Gallen, , Switzerland
London, England, United Kingdom
London, England, United Kingdom
London, England, United Kingdom
Manchester, England, United Kingdom
Glasgow, GB, United Kingdom
Leeds, GB, United Kingdom
Leeds, GB, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007 Oct 1;45(7):883-93. doi: 10.1086/520980. Epub 2007 Aug 29.
Shorr AF, Wu C, Kothari S. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei. J Antimicrob Chemother. 2011 Feb;66(2):375-80. doi: 10.1093/jac/dkq446. Epub 2010 Dec 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
03-0-192
Identifier Type: -
Identifier Source: org_study_id
NCT00235742
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.